Pesquisar
Serina Therapeutics Inc
SERAdicionar à lista de desejos
1.640USD
-0.080-4.65%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
24.60MValor de mercado
PerdaP/L TTM
Mais detalhes de Serina Therapeutics Inc Empresa
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Informações de Serina Therapeutics Inc
Código da empresaSER
Nome da EmpresaSerina Therapeutics Inc
Data de listagemNov 29, 2018
CEOLedger (Steven)
Número de funcionários12
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 29
Endereço601 Genome Way,
CidadeHUNTSVILLE
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal35806
Telefone12563279630
Sitehttps://serinatherapeutics.com/
Código da empresaSER
Data de listagemNov 29, 2018
CEOLedger (Steven)
Executivos da empresa Serina Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
126.91K
+47.02%
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Independent Director
Independent Director
7.55K
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
126.91K
+47.02%
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Independent Director
Independent Director
7.55K
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Detalhamento da receita
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
130.00K
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Juvenescence Ltd
21.93%
Sio Capital Management, LLC
6.71%
Puffinus L.P.
6.07%
McMillan (Helen w)
4.76%
Vanguard Capital Management, LLC
1.07%
Outro
59.46%
Investidores
Investidores
Proporção
Juvenescence Ltd
21.93%
Sio Capital Management, LLC
6.71%
Puffinus L.P.
6.07%
McMillan (Helen w)
4.76%
Vanguard Capital Management, LLC
1.07%
Outro
59.46%
Tipos de investidores
Investidores
Proporção
Corporation
28.00%
Hedge Fund
7.08%
Individual Investor
6.30%
Investment Advisor
2.03%
Investment Advisor/Hedge Fund
0.51%
Research Firm
0.02%
Outro
56.04%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
53
1.62M
10.86%
+1.12M
2025Q4
56
455.00K
4.27%
-38.88K
2025Q3
56
464.13K
4.40%
+21.47K
2025Q2
59
6.70M
67.24%
+256.13K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Juvenescence Ltd
3.27M
26.53%
--
--
Sep 17, 2025
Puffinus L.P.
904.88K
7.35%
--
--
Sep 17, 2025
McMillan (Helen w)
708.61K
5.75%
-133.79K
-15.88%
Sep 17, 2025
Bailey (Gregory Hugh)
67.24K
0.55%
--
--
Sep 17, 2025
Ledger (Steven A)
95.73K
0.78%
-227.93K
-70.42%
Sep 17, 2025
Waverly Advisors, LLC
67.49K
0.55%
--
--
Dec 31, 2025
Broadwood Capital, Inc.
54.48K
0.44%
-28.71K
-34.51%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Data
Data ex-dividendo
Tipo
Proporção
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
